OmniAb Announces $30 Million Private Placement

EMERYVILLE, Calif.--(BUSINESS WIRE)--$OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expenses. The net proceeds from the financing are expected to be used by OmniAb for general corporate purposes. The private placement is expected to close on or about August 26, 2025, subject to customary closing conditions.

The financing included top-tier new and existing investors, as well as officer and director participation.

Leerink Partners is acting as the sole placement agent for the private placement.

The shares of common stock to be sold in this financing have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Pursuant to the purchase agreement, OmniAb has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock sold in the private placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the common stock, nor shall there be any offer, solicitation, or sale of the common stock in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About OmniAb®

OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

Contacts

Contacts

OmniAb, Inc. [email protected] X @OmniAbTech

Alliance Advisors IR Yvonne Briggs [email protected] (310) 691-7100